Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

3 US Stocks to Watch if the Democrats Win the 2025 Election

With the 2025 U.S. presidential election on the horizon, investors are keeping a close eye on how a Democratic win could impact the markets. Renewable energy, healthcare, as well as infrastructure are the usual focus areas of Democratic policies and all are vying for growth if the party wins the White House. In this article,…

ByUjjwal MaheshwariOctober 5, 2024

Want to participate in the ASX Schools Sharemarket Game? Here are Some Top Strategies for Success!

The ASX Schools Sharemarket Game is on again! And it is a great way for school students to be introduced to the strategic functioning of the share markets. But just because you're not using actual money, it doesn't mean you should take it seriously. This blog will identify the best practices to assist you in…

ByUjjwal MaheshwariOctober 1, 2024

Here Are The Top 5 Websites for Stock Market News & Analysis in Australia

For Australian investors and traders, staying informed about stock market news is essential for making smart decisions. With a range of websites now providing real-time data, expert analysis, and market insights, investors have the tools to navigate the ever-changing world of stocks. This article highlights five of the most reliable websites offering stock market news…

ByUjjwal MaheshwariSeptember 25, 2024

Should you invest in aged care stocks? Here are 4 reasons to consider them, and 4 reasons to avoid them

Should you invest in aged care stocks? There are plenty of things to like about this sector, including government funding, resilience to tough economic times and the growth in demand that will come as the Baby Boomers age. But it is not all. Should you invest in aged care stocks? The Yes case 1. Ageing population…

ByNick SundichSeptember 17, 2024

Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs

For ASX biotechs wishing to commercialise drugs in Australia, the Therapeutic Goods Administration (TGA) Special Access Scheme is the next best thing to regulatory approval. Therapeutic goods need to be included on the Australian Register of Therapeutic Goods (ARTG), prior to being sold, imported or exported from Australia. However, the Special Access Scheme provides a way…

ByNick SundichSeptember 16, 2024

The 2024 Pitt Street Research Life Sciences Conference is coming up! And you’re invited!

The Pitt Street Research Life Sciences Conference is happening on September 19, 2024! The Life Sciences sector in Australia and New Zealand continues to mature in 2024. In spite of a difficult market for small-cap stocks on the ASX, companies are making progress in the clinic and management teams are building on their learnings…

ByNick SundichSeptember 13, 2024

Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer

Unless you're a professional dermatologist, you may not have ever heard of Photodynamic Therapy, let alone thought of it as an option to fight cancer as Invion (ASX:IVX) is doing. Invion may not appear to be an appealing investment at first glance, given its status as a 'penny stock' with a share price as a fraction…

ByNick SundichSeptember 9, 2024

Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years

If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something to say about that. You see, any ‘treatments’ that exist are only about addressing the pain or other symptoms rather than being a cure or remission. These treatments tend to need frequent administration or lose effectiveness…

ByNick SundichSeptember 6, 2024

Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017

Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian Government's Office of Drug Control in March 2017. During this time, there have been various busts and booms in the cannabis sector, although there has been little hype since the aftermath of TGA's declassification of certain…

ByNick SundichSeptember 6, 2024

Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate

It has been less then a year since Antisense Therapeutics changed its name to Percheron Therapeutics (ASX:PER). It is common for biotech companies to change their name when they pivot to new indications and/or to new assets, but this was not the case with Percheron. It is still focused on Duchenne Muscular Dystrophy (DMD), a…

ByNick SundichSeptember 3, 2024

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

3 US Stocks to Watch if the Democrats Win the 2025 Election

Here Are The Top 5 Websites for Stock Market News & Analysis in Australia

Should you invest in aged care stocks? Here are 4 reasons to consider them, and 4 reasons to avoid them

Here’s what you need to know about the TGA Special Access Scheme and why its a game changer for ASX biotechs

The 2024 Pitt Street Research Life Sciences Conference is coming up! And you’re invited!

Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer

Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years

Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017

Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here